Table 1.
Summary of included studies, study types, and preoperative predictors
| Author (year) | Study type | Procedure | n | Age | DoD | C-peptide | Baseline BMI | Baseline HbA1c | Insulin use | Sex | Race | Scoring model |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chikunguwo et al. (2010)20 | Retrospective | RYGB | 177 | O | O | |||||||
| Hamza et al. (2011)21 | Retrospective | LAGB | 74 | O | O | |||||||
| Hayes et al. (2011)22 | Prospective | RYBG, GB | 127 | N | O | O | O | LRM | ||||
| Carlsson et al. (2012)23 | Prospective | RYGB, AGB, VBG | 1,658 | N | O | N | N | |||||
| Jiménez et al. (2012)24 | Prospective | SG | 153 | O | O | O | ||||||
| Lee et al. (2013)25 | Retrospective | RYGB, GB | 63 | O | O | O | O | ABCD | ||||
| Arterburn et al. (2013)26 | Retrospective | RYGB | 4,434 | O | O | O | O | |||||
| Dixon et al. (2013)27 | Retrospective | GB | 154 | O | O | O | N | LRM | ||||
| Aarts et al. (2013)28 | Retrospective | RYGB | 56 | O | N | O | O | |||||
| Ramos-Levi et al. (2014)29 | Retrospective | SG, RYGB, BPD | 141 | O | O | O | N | O | O | O | LRM | |
| Still et al. (2014)30 | Retrospective | RYGB | 690 | O | O | O | O | DiaRem | ||||
| Robert et al. (2013)31 | Retrospective | LAGB, RYBG, SG | 46 | O | O | O | O | |||||
| English et al. (2015)32 | Retrospective | RYGB | 245 | O | ||||||||
| Bhasker et al. (2015)33 | Prospective | RYBG | 102 | O | O | O | O | O | ||||
| Panunzi et al. (2016)34 | Prospective | GB, BPD, LAGB | 415 | O | O | O | O | |||||
| Panunzi et al. (2015)35 | Meta-analysis | SG, LAGB, GB | 4,944 | O | N | O | ||||||
| Wang et al. (2015)19 | Meta-analysis | SG, RYGB | 1,753 | O | O | O | N | O | O | |||
| Ikramuddin et al. (2015)36 | RCT | RYGB | 60 | O | N | |||||||
| Schauer et al. (2017)4 | RCT | GB, SG | 134 | N | O | N | N | N | N | N | N | |
| Park et al. (2016)37 | Retrospective | RYGB | 134 | O | O | O | O | LRM | ||||
| Scopinaro et al. (2017)38 | Retrospective | BPD | 135 | O | O | |||||||
| Praveen Raj et al. (2017)39 | Retrospective | RYGB, SG | 53 | N | N | O | ||||||
| Aron-Wisnewsky et al. (2017)17 | Retrospective | RYGB | 213 | O | O | O | O | Ad-DiaRem | ||||
| Aminian et al. (2017)40 | Retrospective | RYGB, SG | 659 | O | O | O | IMS score | |||||
| Naitoh et al. (2018)41 | Retrospective | SG, GB | 298 | O | O | O | ||||||
| Huang et al. (2018)42 | Meta-analysis | SG, GBn | 1,160 | O | O | |||||||
| Stallard et al. (2018)43 | Retrospective | RYGB, SG | 98 | O | O | N | O | |||||
| Pucci et al. (2018)44 | Retrospective | RYGB, SG | 210 | O | O | O | DiaBetter | |||||
| Madsen et al. (2019)18 | Matched cohort | RYGB | 1,111 | O | O | O | O | O | O | |||
| Shen et al. (2019)45 | Retrospective | SG | 128 | O | O | O | O |
DoD, duration of diabetes; BMI, body mass index; HbA1c, glycosylated hemoglobin; O, effect; N, neutral effect; Blank, not assessed/unclear; RYGB, Roux-en-Y gastric bypass; LAGB, Laparoscopic Adjustable Gastric Banding; GB, bypass surgery (unspecified); LRM, logistic regression model; AGB, adjustable gastric banding; VBG, vertical gastric banding; SG, sleeve gastrectomy; BPD, biliopancreatic diversion; Ad-DiaRem, advanced-DiaRem; IMS, individualized metabolic surgery; GBn, gastric bypass-non-specified.